Xin Lang Cai Jing·2025-12-30 09:59Core Viewpoint - The company announced that its wholly-owned subsidiary, Luling Kewhua, has acquired the marketing authorization and related production technology for Mesalazine enteric-coated tablets (0.5g specification) from Lifan Pharmaceutical for 34 million yuan (including tax) [1] Group 1: Transaction Details - The acquisition involves a change of the marketing authorization holder, which requires approval from the National Medical Products Administration [1] - The transaction does not constitute a related party transaction or a major asset restructuring [1] - The payment for the contract is divided into three installments, and the contract is valid until the marketing authorization holder is changed to Luling Kewhua and the production site is changed or increased to a designated site, completing verification of three batches of production and passing inspection [1] Group 2: Strategic Implications - The transaction aims to implement the "One Elderly" strategy, enrich the product pipeline, and strengthen the company's advantage in gastrointestinal medications [1]